CLDI

Healthcare Biotechnology

Calidi Biotherapeutics, Inc.

$1.05

-0.03 -2.78% today

Price History

Not enough data

Key Stats

Market Cap

3.86M

Avg Volume

259,671

EPS

-$36.47

52W High

$27.84

52W Low

$1.03

Div. Yield

0.0%

Valuation

Forward P/E

-1.17

P/B Ratio

0.70

EV/EBITDA

-0.04

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(672.2%)

Return on Assets

(134.8%)

Liquidity & Leverage

Current Ratio

1.68

Quick Ratio

1.34

Debt / Equity

0.62

Total Cash

4.07M

Total Debt

1.94M

About

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.